1. A phase II open‐label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. (23rd May 2013) Authors: Daver, N.; Vega‐Ruiz, A.; Kantarjian, H.M.; Estrov, Z.; Ferrajoli, A.; Kornblau, S.; Verstovsek, S.; Garcia‐Manero, G.; Cortes, J.E. Journal: European journal of cancer care Issue: Volume 22:Number 5(2013:Sep.) Page Start: 605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation‐positive myeloproliferative neoplasm. (18th June 2015) Authors: Chen, Z.; Wang, W.; Verstovsek, S.; Cortes, J. E.; Medeiros, L. J.; Hu, S. Journal: International journal of laboratory hematology Issue: Volume 37:Number 6(2015:Dec.) Page Start: e150 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Highly Reproducible Detection and Semi-Quantification of Telomerase Activity. (May 2001) Authors: Verstovsek, S.; Manshouri, T.; Kantarjian, H.; Giles, F.J.; Keating, M.; Estey, E.; Albitar, M. Journal: Biotechniques Issue: Volume 30:Number 5(2001) Page Start: 930 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Issue 7 (July 2015) Authors: Gowin, K.; Verstovsek, S.; Daver, N.; Pemmaraju, N.; Valdez, R.; Kosiorek, H.; Dueck, A.; Mesa, R. Journal: Leukemia research Issue: Volume 39:Issue 7(2015:Jul.) Page Start: 684 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA. (23rd June 2022) Authors: Kuykendall, A.; Kremyanskaya, M.; Ginsburg, Y.; Pemmaraju, N.; Ritchie, E.; Gotlib, J.; Valone, F.; Khanna, S.; Gupta, S.; Hoffman, R.; Verstovsek, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 918 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS. (23rd June 2022) Authors: Gupta, V.; Mascarenhas, J.; Kremyanskaya, M.; Rampal, R. K.; Talpaz, M.; Kiladjian, J.-J.; Vannucchi, A.; Verstovsek, S.; Colak, G.; Dey, D.; Harrison, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 919 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS. (23rd June 2022) Authors: Harrison, C.; Rampal, R. K.; Gupta, V.; Verstovsek, S.; Talpaz, M.; Kiladjian, J.-J.; Mesa, R.; Kuykendall, A.; Vannucchi, A.; Palandri, F.; Grosicki, S.; Devos, T.; Jourdan, E.; Wondergem, M. J.; Al-Ali, H. K.; Buxhofer-Ausch, V.; Alvarez-Larrán, A.; Akhani, S.; Muñoz-Carerras, R.; Sheykin, Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES. (23rd June 2022) Authors: Harrison, C.; Kiladjian, J.-J.; Vannucchi, A. M.; Mesa, R. A.; Scherber, R. M.; Hamer-Maansson, J.; Verstovsek, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 927 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS. (23rd June 2022) Authors: Kiladjian, J.-J.; Tefferi, A.; Passamonti, F.; Vannucchi, A.; Talpaz, M.; Cervantes, F.; Harrison, C. N.; Mesa, R. A.; Mascarenhas, J.; Schaap, N.; Verstovsek, S.; Devos, T.; Rose, S.; Zhang, J.; Sy, O.; Pardanani, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX). (23rd June 2022) Authors: Gupta, V.; Yacoub, A.; Verstovsek, S.; Mesa, R. A.; Harrison, C. N.; Barosi, G.; Kiladjian, J.-J.; Deeg, H. J.; Fazal, S.; Foltz, L.; Mattison, R. J.; Miller, C. B.; Parameswaran, V.; Hernandez, C.; Zhang, J.; Talpaz, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 932 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗